

## TEST REPORT

### Neurocysticercosis IgG ELISA

**Patient Name:** John Doe **Date of Birth:** 5-May-1956  
**Patient Address:** 1 Main Street Megapolis, CA 00122 **Sample ID:** NCC APA23-05  
**Provider Name:** Dr. Who  
**Provider Facility:** Main Hospital Lab

	TEST RESULT	Reference Interval
Neurocysticercosis (NCC) IgG ELISA	<b>NEGATIVE</b>	<b>NEGATIVE</b>
<i>NCC IgG ELISA Index</i>	<b>0.1</b>	<b>0.0 - 0.9</b>

NCC Index	Interpretation
<b>&lt; 0.9</b>	<b>Negative*</b> No antibody to the <i>T. solium</i> antigens detected in the present assay.
<b>0.9 - 1.1</b>	<b>Indeterminate / Equivocal</b> Equivocal samples should be retested and interpreted as positive or negative according to the retest Index value. If the Index value of the retested sample remains in the Equivocal zone, the sample should be tested with an alternative assay or a second sample should be drawn and re-tested.
<b>&gt; 1.1</b>	<b>Positive**</b> Antibody to the <i>T. solium</i> antigens detected in the present assay.

\* A negative result does not exclude the possibility of infection

\*\* The diagnosis of neurocysticercosis should be made based on history, symptoms, and imaging data, in addition to the presence of antibodies to *T. solium* antigens.

Test Code	Sample Accession #	Sample Collected Date	Sample Received Date	Test Completed Date	Test Reported Date
NCC Ab	2307130005	10-Jul-2023	13-Jul-2023	14-Jul-2023	17-Jul-2023

This test was established and validated by Kephera Diagnostics, LLC, 1 Grant Street, Framingham, MA 01702 (CLIA ID #22D2182419), Laboratory Director: Andrew E Levin, PhD. Its performance was determined to be pursuant to the requirements of CLIA '88 for clinical testing.  
The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).